I-Mab stock surges on Lucid Capital's buy rating initiation

I-Mab shares surged 16.4% following a Buy rating from Lucid Capital Markets, with a $5.00 price target, driven by optimism surrounding its Claudin18.2 x 4-1BB bispecific antibody, Givastomig; Phase 1b data for Givastomig in advanced gastric cancer is expected in the second half of 2025 and the first half of 2026, with potential peak sales estimated at $2.6 billion by 2040. The analyst also cited I-Mab's strong cash position of $168.6 million, providing runway into 2027.

Analysis

I-Mab's (NASDAQ:IMAB) shares experienced a significant 16.4% appreciation following a new 'Buy' rating and a $5.00 price target initiation by Lucid Capital Markets. This positive market reaction is primarily attributed to the anticipated potential of I-Mab's lead cancer therapeutic, Givastomig, a Claudin18.2 x 4-1BB bispecific antibody. Key upcoming catalysts for Givastomig include the expected top-line Phase 1b combination dose escalation and dose expansion data in advanced gastric cancer patients in the second half of 2025 and the first half of 2026, respectively, with preliminary data also slated for presentation at the ESMO GI 2025 conference. The analyst projects peak sales for Givastomig in gastric cancer alone could reach approximately $2.6 billion by 2040. The $5 price target is substantially driven by Givastomig, valued at roughly $4 per share, with the remaining $1 per share attributed to earlier pipeline assets and platform value, including uliledlimab and ragistomig. Further upside to this valuation is noted if Givastomig demonstrates success in other indications like pancreatic cancer and cholangiocarcinoma. I-Mab's financial stability, with reported cash and equivalents of approximately $168.6 million in Q1 2025, provides a runway through these critical data readouts and into 2027, supporting its development pipeline.

Key Decisions for Investors

• Investors should consider the significant catalyst-driven potential of I-Mab, primarily linked to the clinical development and future commercialization of Givastomig, while noting the stock's recent price surge reflects heightened expectations.
• It is crucial to monitor upcoming clinical trial data readouts for Givastomig, particularly in H2 2025 and H1 2026, as these will be key inflection points for the company's valuation and future prospects.
• The company's current cash runway into 2027 is a positive factor, but investors should remain aware of the long-term nature of biopharmaceutical development and the inherent risks associated with clinical trial outcomes and eventual market adoption, especially given the concentration of value in a single lead asset within the current price target.